Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kbio Holdings Limited is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. AGNIESZKA BOESEN is the busiest examiner for the company, with 1 pending action. The portfolio involves a distinct examiner and a distinct art unit, indicating a focused prosecution effort on a single matter within the specialized biotechnology sector.
Because the company's active filings are limited to a distinct examiner and a distinct art unit, the entire prosecution strategy is centered on the interaction with AGNIESZKA BOESEN. This focus suggests that the company is prioritizing a specific pharmaceutical or biotechnological innovation. For the practitioner, this means that the success of the company's current patent efforts depends on the outcome of this one specific examination process, without the benefit of other concurrent filings to hedge prosecution risk.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, AGNIESZKA | 1 | 68.6% | +21.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18734088 | VIRUS AND ANTIGEN PURIFICATION AND CONJUGATION | BOESEN, AGNIESZKA | 111d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18734088 | VIRUS AND ANTIGEN PURIFICATION AND CONJUGATION | BOESEN, AGNIESZKA | 1672 | §112 | Non-Final OA | 111d overdue | Pending | Jun 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKbio Holdings Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Agnieszka Boesen has the most, with 1 of Kbio Holdings Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.